CHICAGO--(BUSINESS WIRE)--Igenbio, Inc. announced today the release of ERGO 2.0, the latest version of a unique integrated platform that enables industrial, academic, and medical scientists to rapidly develop knowledge from existing and new DNA sequencing projects. ERGO 2.0 will help reduce time to market by saving precious lab effort and resources. ERGO 2.0 contains a massive curated database integrated with state of the art synthetic biology tools enabling faster product creation. Built on a
Igenbio is an Illinois-based biotechnology company that provides functional genomic data, metabolic reconstructions, and expression profiling for the healthcare industry.